AT-7687_Dosage, benefits & legal status
Also known as AT7687
An experimental weekly shot that blocks the GIP receptor, the opposite of what tirzepatide does.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is AT-7687?
Plain language first. The technical label stays, but it never stands alone.Overview
Tirzepatide switches the GIP receptor on and this switches it off, yet both approaches have added to GLP-1 weight loss in animals. A 102-person phase 1 found it well tolerated, and a phase 2a testing it on top of semaglutide began in June 2026. There is no human weight-loss result yet, and it is not approved anywhere.
AT-7687 is a GIP receptor antagonist: a lipidated analogue of the natural blocker GIP(3-30), developed by Antag Therapeutics in Copenhagen from University of Copenhagen research.
What it's used for
An experimental weekly add-on to GLP-1 drugs for weight loss. In obese monkeys it held weight stable on its own; no human efficacy data exist yet.
How does AT-7687 work?
What it does in the body, and where.AT-7687 is a modified fragment of GIP that sits in the GIP receptor without switching it on, so the body's own GIP cannot act.
- 01Competitive blockerIn cell assays it bound the human GIP receptor tightly (Ki 2 nM) and blocked GIP's signal with no activity of its own. It did nothing at the GLP-1, GLP-2 or glucagon receptors.
- 02Why block GIPGIP helps the body store fat. Mice lacking GIP signalling resist obesity, antibodies that block the receptor prevent weight gain in obese animals, and people with gene variants that weaken the receptor tend to carry less fat.
- 03The paradoxTirzepatide switches the same receptor on and also adds to GLP-1 weight loss. One unproven explanation is that constant stimulation wears out the fat-cell receptor until it behaves as if blocked. Antag's own authors call the question controversial.
- 04Fatty tailA lipid makes it bind albumin tightly (0.2% unbound in plasma). Its half-life was about 27 hours in monkeys, and the company says human exposure fits weekly dosing.
A schematic of the compound's mechanism, not a diagnostic image.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Monkeys with a GLP-1 drug
Early research- Animal studyObese male cynomolgus monkeys, 42 days, about 10 per group: placebo gained 8.6%, AT-7687 alone held weight stable, liraglutide lost 12.4% and the combination 16.3% against placebo. The combination was not significantly better than liraglutide alone.
- Animal studyAgainst placebo, the combination cut insulin 52%, triglycerides 39% and LDL cholesterol 48%. AT-7687 alone also lowered LDL.
- Animal studyNo vomiting, diarrhoea or behaviour changes in monkeys on AT-7687, and bone markers were unchanged.
In people so far
Investigational- human-earlyPhase 1 in 102 lean and obese volunteers: no serious adverse events, no dropouts for side effects, and mild stomach effects as common as on placebo, according to the company.
- No dataNo doses, weight changes or adverse event rates from phase 1 have been published, and there is no journal paper.
Agonist or antagonist
Early research- Human observationGIP receptor gene variants that weaken both of its signalling routes are associated with lower adiposity in people (Nature Metabolism 2024).
- Lab studyChronic GIP receptor stimulation desensitised fat-cell receptors in one study; the authors describe this as mimicking functional antagonism. This is a hypothesis to reconcile the two approaches, not a settled answer.
AT-7687 did not cause weight loss on its own in monkeys: it held weight stable while the placebo group gained 8.6%. The 16.3% figure is the combination with liraglutide against placebo, and it was not statistically different from liraglutide alone. The 12.2% against 7.8% cagrilintide result is a from-baseline figure from an unpublished poster. 'No stomach side effects' overstates phase 1; the company says they were mild and as common as on placebo. The 27-hour half-life is from monkeys dosed daily; no human half-life has been published. The phase 2a has three arms, not the two the company release describes. Do not confuse it with AZD7687 (an AstraZeneca oral drug) or AT7867 (a kinase inhibitor).
The published record
Papers and trials about AT-7687
3 papers tagged human · 2 not reviews or lab · 0 clinical trial publications
1 registered trials · none with posted results
Furthest stage reached: Phase 2, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count. 3 papers and 1 trials indexed in detail.
At a glance
Four things to know about AT-7687
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Not published in people (about 27 hours in monkeys)
How much, and do you cycle it?
The range, and whether you take breaks.25 or 50 mg weekly (phase 2 doses), weekly. Not cycled in the trials Trial dose
Given weekly for 13 weeks in the phase 2a, on top of semaglutide, with no break.
How long does it stay in the body?
The half-life, and where the figure comes from.Not published in people (about 27 hours in monkeys)Trial protocol
The company reports dose-proportional exposure with low variability between people, consistent with weekly injection, and gives no half-life. Animal values: 27.4 hours in monkeys and 58 hours in minipigs.
Source: Antag Therapeutics, January and June 2026 releases (exposure consistent with weekly dosing); Jensen et al., Mol Metab 2024 (monkey 27.4 hours, minipig 58 hours)
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Dry powder in the freezer or fridge. Once mixed, fridge, and use within about a month.
Unmixed lyophilized AT-7687 keeps for a long time cold. Once you add water the clock starts: most reconstituted vials hold up for roughly 28 to 30 days at fridge temperature. Keep it out of light, and do not freeze it after mixing.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- A personal or family history of medullary thyroid cancer or MEN 2, excluded from the phase 2a, where everyone also takes semaglutide
- Pancreatitis, chronic or within the last six months
- Reduced kidney function (eGFR below 60), excluded from the phase 2a
- Pregnancy or breastfeeding, since no reproductive safety data exist
Stop and get help
- Spreading hives, swelling of the face or throat, or trouble breathing
- Severe stomach pain spreading to your back, a risk of the semaglutide it is paired with
- Vomiting badly enough that you cannot keep fluids down
Common effects
- Stomach side effects that the company describes as mild and equally split between drug and placebo in the 102-person phase 1
- No severe or serious adverse events and no one stopping for side effects in phase 1
- Rates and percentages have not been published
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is AT-7687 approved?
And where the numbers on this page come from.No. AT-7687 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked11 October 2026
- DoseFrom published clinical trials. Not approved by a regulator for this dose.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesJensen MH et al., Molecular Metabolism 2024;88:102006ClinicalTrials.gov, NCT07724340Antag Therapeutics, phase 1 results (January 2026)Antag Therapeutics, ADA 2026 phase 1 presentation (June 2026)Antag Therapeutics, first phase 2a patient dosed (28 Jul 2026)Antag Therapeutics, FDA IND clearance (9 Oct 2024)Killion EA et al., Science Translational Medicine 2018WO2021110845, Optimized GIP peptide analogues (Antag Therapeutics)
What has happened recently
Not approved anywhere. The FDA accepted its IND in October 2024. Phase 1 (102 lean and obese healthy volunteers, single and multiple doses) finished in late 2025 and was presented at ADA in June 2026. A 150-person phase 2a in type 2 diabetes with obesity, on semaglutide, started on 19 June 2026 at eight US sites (NCT07724340), with topline results expected in the first half of 2027. On ClinicalTrials.gov the drug is named AT673, not AT-7687; Antag's own release links that trial to AT7687, and nothing published explains the different code.
You can compare this against the whole library, or read how to check a seller.
What else is like AT-7687?
Others in Fat loss without GLP-1, side by side.If you're weighing AT-7687, it's worth reading Irisin, Setmelanotide (Imcivree), and Spexin in the same class.
An experimental weekly shot that blocks the GIP receptor, the opposite of what tirzepatide does.
- Dose
- 25 or 50 mg weekly (phase 2 doses)
- How often
- Weekly
The exercise-in-a-pill myokine, and a decade-long argument about whether the tests for it work.
- Dose
- Research only
- How often
- Not established
An approved daily shot for rare genetic forms of obesity.
- Dose
- 2 up to 3 mg per day (start low, increase slowly)
- How often
- Daily
An appetite peptide found by computer search, still almost entirely in animals.
- Dose
- Research only
- How often
- Not established
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Jensen MH et al., Molecular Metabolism 2024;88:102006(2024)Competitive human GIP receptor antagonist (Ki 2 nM, pKB 9.5). In obese cynomolgus monkeys over 42 days: placebo gained 8.6%, AT-7687 alone held weight stable, liraglutide lost 12.4% and the combination 16.3% against placebo; the combination did not differ significantly from liraglutide alone. Half-life 27.4 hours in monkeys.
- ClinicalTrials.gov, NCT07724340(2026)Phase 2a, 150 people with type 2 diabetes and BMI 27 or more, 1:1:1 to AT673 25 mg, 50 mg or placebo weekly, all on semaglutide. Primary endpoint: % body weight change at week 13. Started 19 June 2026.
- Antag Therapeutics, phase 1 results (January 2026)(2026)102 participants, combined single and multiple ascending doses, 4 weeks of multiple dosing. No severe or serious adverse events, no discontinuations for adverse events, and stomach events mild and equally distributed between drug and placebo.
- Antag Therapeutics, ADA 2026 phase 1 presentation (June 2026)(2026)Oral presentation describing it as well tolerated and suitable for once-weekly injection, with dose-proportional exposure. Monkey study with cagrilintide: 12.2% weight loss from baseline on the combination against 7.8% on cagrilintide alone over 42 days (poster, not peer reviewed).
- Antag Therapeutics, first phase 2a patient dosed (28 Jul 2026)(2026)Links NCT07724340 to AT7687 and expects topline results in the first half of 2027.
- Antag Therapeutics, FDA IND clearance (9 Oct 2024)(2024)IND accepted; phase 1 planned in lean and obese volunteers and with semaglutide in obese volunteers.
- Killion EA et al., Science Translational Medicine 2018(2018)Antibodies that block the GIP receptor prevented weight gain in obese animal models, and the effect was larger with a GLP-1 agonist.
- WO2021110845, Optimized GIP peptide analogues (Antag Therapeutics)(2021)Claims GIP(3-30) analogues with fatty acid attachment and specific substitutions. Shows the parent GIP(3-30) sequence; does not identify which claimed compound is AT-7687.
Beyond these, 4 records are indexed. Browse the records